OCA
DTIL icon

Octagon Capital Advisors’s Precision BioSciences DTIL Stock Holding History

Octagon Capital Advisors’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6M Sell
1,350,000
-886,732
-40% -$6.24M 0.95% 20
2026
Q1 		$12.3M Buy
2,236,732
+318,737
+17% +$1.47M 1.36% 21
2025
Q4 		$7.98M Buy
+1,917,995
New +$10.9M 0.97% 24

Other funds holding DTIL

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Octagon Capital Advisors's DTIL Position: Q2 2026 in Review

Octagon Capital Advisors reduced its Precision BioSciences (DTIL) stake by 40% in Q2 2026, selling an estimated $6.24M and leaving 1,350,000 shares worth $10.6M. The position accounts for 0.95% of the portfolio, ranked #20.

Octagon Capital Advisors first reported a position in DTIL in Q4 2025 and has held it in 3 quarters since. The position peaked at $12.3M in Q1 2026. 95 funds tracked by Wall St. Rank hold DTIL as of Q2 2026.

  • Octagon Capital Advisors held 1,350,000 shares of Precision BioSciences worth $10.6M as of Q2 2026.
  • Octagon Capital Advisors sold 886,732 Precision BioSciences shares in Q2 2026, an estimated $6.24M.
  • Precision BioSciences made up 0.95% of Octagon Capital Advisors's portfolio in Q2 2026, its #20 holding.
  • Octagon Capital Advisors first reported a position in Precision BioSciences in Q4 2025 and has held it in 3 quarters since.
  • Octagon Capital Advisors's Precision BioSciences position peaked at $12.3M in Q1 2026.
  • 95 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2026.

Based on Octagon Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.